305 related articles for article (PubMed ID: 18698245)
1. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Nair S; Lipscomb J; Eason J
Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
[TBL] [Abstract][Full Text] [Related]
2. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
3. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
4. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Habrecht O; Settmacher U
Transplantation; 2008 Aug; 86(3):469-73. PubMed ID: 18698252
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
[TBL] [Abstract][Full Text] [Related]
8. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
10. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
[TBL] [Abstract][Full Text] [Related]
11. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
12. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Bizollon T; Adham M; Pradat P; Chevallier M; Ducerf C; Baulieux J; Zoulim F; Trepo C
Transplantation; 2005 Feb; 79(3):325-9. PubMed ID: 15699763
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
[TBL] [Abstract][Full Text] [Related]
14. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Calmus Y; Duvoux C; Pageaux G; Wolf P; Rostaing L; Vanlemmens C; Botta-Fridlund D; Dharancy S; Gugenheim J; Durand F; Néau-Cransac M; Boillot O; Chazouillères O; Samelson L; Boudjema K; Samuel D
J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001
[TBL] [Abstract][Full Text] [Related]
16. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
[TBL] [Abstract][Full Text] [Related]
19. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Liver Int; 2006 Jun; 26(5):529-35. PubMed ID: 16761996
[TBL] [Abstract][Full Text] [Related]
20. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Maynard M; Pradat P; Bailly F; Rozier F; Nemoz C; Si Ahmed SN; Adeleine P; Trépo C;
J Hepatol; 2006 Mar; 44(3):484-90. PubMed ID: 16426697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
